Sana Biotechnology Inc Dossier
Qualitative Analysis
Business overview
Sana Biotechnology, Inc. is a clinical-stage biotechnology company focused on creating and delivering engineered cells as medicines for patients. The company utilizes both ex vivo and in vivo cell engineering platforms to develop therapies across major therapeutic areas with significant unmet medical needs, including type 1 diabetes (T1D), oncology, and B-cell-mediated autoimmune diseases. Sana's core technological focus is its proprietary hypoimmune (HIP) platform, designed to engineer allogeneic cells that can evade the patient's immune system to prevent rejection and ensure long-term persistence without the need for immunosuppressive drugs. Additionally, its in vivo CAR T platform utilizes CD8-targeted fusosomes to deliver genetic payloads directly to T cells inside the patient's body.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic pivot to concentrate resources on the development of therapies for type 1 diabetes (such as SC451 and UP421) and B-cell mediated autoimmune diseases (such as SC291), while suspending or seeking partners for certain oncology programs.
Expected impact: Extends the company's cash runway into 2027 and focuses clinical development on high-probability, high-impact therapeutic areas.
Advancing the fusogen platform to enable cell-specific, in vivo delivery of genetic payloads, specifically focusing on the CD19-directed candidate SG293.
Expected impact: Establishes a differentiated, off-the-shelf in vivo CAR T therapy that avoids the complex manufacturing and patient conditioning required for ex vivo CAR T.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Focuses on accelerating the development, validation, and standardization of protocols for SC451, Sana's stem cell-derived pancreatic islet cell therapy for type 1 diabetes.
Terms: Mayo Clinic made an initial $25.0 million equity investment (purchasing 7,507,507 shares at $3.33 per share) with an option to invest an additional $25.0 million on or before August 31, 2026.
Terms: Sana received a $100.0 million upfront payment and has received $105.0 million in subsequent R&D milestones through December 31, 2025, with eligibility for up to $125.0 million in additional milestone payments plus tiered royalties on future sales.